The authors look at key factors driving the risk-sharing agreements that have been implemented to reduce drug expenditures across Europe.
Michael N. Abrams
Advertisement
Articles by Michael N. Abrams
The biopharmaceutical industry contemplates product innovation within the changing landscape of healthcare.
Advertisement
Latest Updated Articles
The Affordable Care Act's Impact on Innovation in BiopharmaFebruary 2nd 2014
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Zumilokibart: Inside AbbVie's $10.9B Pipeline Bet
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
IPEC’s Excipient Information Package: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires
5